Management team

Miriam Bazan-Peregrino

Miriam Bazan-Peregrino

PhD, R&D Manager

Dr. Bazan-Peregrino is an expert in oncolytic virotherapy with more than 15 years of experience in the field. She is author of many original scientific papers and reviews in peer-reviewed journals, and has presented her research work in a large number of international conferences. Miriam Bazan-Peregrino is inventor on patents related to oncolytic adenoviruses as anti-cancer agents. Dr. Bazan-Peregrino joined VCN Biosciences in 2014 to head the R&D Department. She strategically plans and executes R&D activities bringing new oncolytic viruses from bench to bedside. She leads a research team of postdoctoral and predoctoral fellows that focus on the translational development of these new treatments. She also closely collaborates with other departments, such as the Regulatory Affairs, CMC and Clinical Research. Her scientific interests include enhancing systemic delivery of oncolytic adenoviruses, anti-angiogenic therapies, boosting immune responses against the tumour, adenoviral spread within the tumour and adenoviral immune evasion.

Prior to VCN Biosciences, she was awarded a DPhil in Clinical Pharmacology from the University of Oxford in the UK and specialized in genetically modifying oncolytic adenoviruses to express different types of therapeutic transgenes for the treatment of cancer. During her post-doctoral research work she was awarded different fellowships such as the Bellhouse Research Fellow by Examination in Biomedical Engineering at Magdalen College (University of Oxford, UK) and the Marie Curie Intra-European Research Fellow at Institut d’Investigació Biomèdica de Bellvitge (Barcelona, Spain).